Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirzepatide for reduction of cardiovascular morbidity and mortality in adults with obesity or overweight
jRCT2031220466Phase 3Active, not recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2022
- Modality
- Recombinant Proteins and Enzymes, Peptides
01
Overview
Phase 3, randomised, double-blind trial in obesity, Overweight and cardiac morbidity comparing Tirzepatide with Placebo (2 arms). Primary endpoint: Time to first occurrence of composite cardiovascular outcome. Started Dec 2022; status: active, not recruiting.
02
Drugs
03
Conditions
obesityOverweightcardiac morbidity
Beyond the preview
Go deeper on jRCT2031220466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031220466.